ITGAM and cancer: Most studies have been focused on myeloid and maturation markers (such as CD10, CD11b, CD15 and CD16, CXCR4, PDL-1) (22, 33, 35) and there is a lack of unbiased analysis of neutrophil heterogeneity in circulation in the setting of cancer.